pyrimethamine has been researched along with Amyotrophic Lateral Sclerosis in 4 studies
Maloprim: contains above 2 cpds
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyrimethamine was measured in plasma and CSF." | 6.84 | Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. ( Ajroud-Driss, S; Andersen, PM; Appel, SH; Doretti, A; Fields, KG; Lange, DJ; Ludolph, AC; Maderna, L; Marklund, SL; Messina, S; Morelli, C; Remanan, R; Shahbazi, M; Silani, V; Weiland, U; Weishaupt, JH, 2017) |
| "Pyrimethamine was measured in plasma and CSF." | 2.84 | Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. ( Ajroud-Driss, S; Andersen, PM; Appel, SH; Doretti, A; Fields, KG; Lange, DJ; Ludolph, AC; Maderna, L; Marklund, SL; Messina, S; Morelli, C; Remanan, R; Shahbazi, M; Silani, V; Weiland, U; Weishaupt, JH, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lange, DJ | 2 |
| Shahbazi, M | 1 |
| Silani, V | 1 |
| Ludolph, AC | 1 |
| Weishaupt, JH | 1 |
| Ajroud-Driss, S | 1 |
| Fields, KG | 1 |
| Remanan, R | 2 |
| Appel, SH | 1 |
| Morelli, C | 1 |
| Doretti, A | 1 |
| Maderna, L | 1 |
| Messina, S | 1 |
| Weiland, U | 1 |
| Marklund, SL | 1 |
| Andersen, PM | 2 |
| Wright, PD | 1 |
| Huang, M | 1 |
| Weiss, A | 1 |
| Matthews, J | 1 |
| Wightman, N | 1 |
| Glicksman, M | 1 |
| Brown, RH | 1 |
| Marklund, S | 1 |
| Benjamin, D | 1 |
| Guerrieri, D | 1 |
| Ferrari, S | 1 |
| Costi, MP | 1 |
| Michels, PA | 1 |
2 trials available for pyrimethamine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Female; Folic Acid Antagonists; Humans; Male; Middle Age | 2017 |
Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Female; Humans; Leukocytes; Male; Middle Age | 2013 |
2 other studies available for pyrimethamine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models.
Topics: Amyotrophic Lateral Sclerosis; Animals; Blotting, Western; Drug Evaluation, Preclinical; Folic Acid | 2010 |
Biochemical effects of riluzole on Leishmania parasites.
Topics: Amyotrophic Lateral Sclerosis; Anticonvulsants; Antiprotozoal Agents; Cell Line; Enzyme Inhibitors; | 2013 |